Patents Examined by Karl J. Puttlitz
  • Patent number: 11180385
    Abstract: The present invention relates generally to stable percarboxylic acid compositions comprising, inter alia, at least two stabilizing agents, and various uses for water treatments, including water treatments in connection with oil- and gas-field operations. The present invention also relates to slick water compositions and gel based compositions that comprise stable percarboxylic acid compositions and the use thereof in oil- and gas-field operations.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: November 23, 2021
    Assignee: ECOLAB USA, INC.
    Inventors: Junzhong Li, David McSherry, Allison Brewster, Richard Staub, Renato De Paula, John Wilhelm Bolduc, Robert J. Ryther, Victor V. Keasler
  • Patent number: 11173214
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 16, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Patent number: 11141432
    Abstract: Provided herein are materials and methods for treating a cancer and/or an infection in a mammal. One or more mitochondrial protein uncoupling protein 2 (UCP2) inhibitors can be administered to a mammal to enhance an immune response produced against an antigen (e.g., a tumor associated antigen or a pathogen associated antigen) present within the mammal.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: October 12, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Protul Shrikant, Leena Chaudhuri
  • Patent number: 11141483
    Abstract: Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: October 12, 2021
    Assignee: Rakuten Medical, Inc.
    Inventors: Lewis R. Makings, Roger Heim, Miguel Garcia-Guzman
  • Patent number: 11137405
    Abstract: Lung cancer can be detected by measuring sites in pancreatic ribonuclease 1 (also abbreviated as “RNase 1”), wherein each of the sites is a site capable of being modified with an N-linked sugar chain. Lung cancer is detected by measuring items A and B as mentioned below and then comparing the ratio of the value of A to the value of B: A=the amount of sites in pancreatic ribonuclease 1, wherein the sites are sites each capable of being modified with an N-linked sugar chain and each having an N-linked sugar chain bound thereto or each having an N-linked sugar chain unbound thereto; and B=the amount of sites in pancreatic ribonuclease 1, wherein the sites are sites each capable of being modified with an N-linked sugar chain.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: October 5, 2021
    Assignee: TOSOH CORPORATION
    Inventor: Daisuke Nakata
  • Patent number: 11136397
    Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 5, 2021
    Assignee: BIRDIE PHARMACEUTICALS, INC.
    Inventor: Lixin Li
  • Patent number: 11135306
    Abstract: An antibody-drug conjugate (ADC) has a structure represented by Formula (I): [D2-L2-Cn2yG2-Ab-Sg1G1-L1-D1]x?? Formula (I) or a pharmaceutically acceptable salt thereof, wherein Ab is an antibody without glycans (i.e., the protein portion of an antibody); G1 and G2 are glycan moieties, which may be the same or different; Cn1 and Cn2 are conjugation moieties, which may be the same or different; L1 and L2 are linker moieties, which may be the same or different; D1 and D2 are drug units which may be the same or different; and x and y are independently an integer from 0 to 8, provided that x+y?0.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: October 5, 2021
    Assignee: CHO PHARMA INC.
    Inventors: Nan-Horng Lin, Charng-Sheng Tsai, Ting-Chun Hung, Hong-Yang Chuang
  • Patent number: 11130818
    Abstract: The present invention provides novel peptide sequences for use in microbial transgluatminase-mediated, in particular mTG2-mediated bioconjugations, in particular for the manufacture of antibody-drug-conjugates. Further disclosed are bioconjugation methods employing mTG2 and the novel peptide sequence motifs of the invention. The present invention further provides proteins comprising the novel sequence motifs of the invention as well as polynucleotides encoding the same.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: September 28, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Birgit Piater, Ulrich Betz, Harald Kolmar, Vanessa Siegmund
  • Patent number: 11130812
    Abstract: The present invention discloses anti-PD-L/PD-1 Axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor/cancer.
    Type: Grant
    Filed: August 29, 2015
    Date of Patent: September 28, 2021
    Assignee: BIRDIE BIOPHARMACEUTICALS, INC.
    Inventors: Lixin Li, Walter Lau
  • Patent number: 11123439
    Abstract: The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: September 21, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Leo Marx, Beatrix Stelte-Ludwig, Carsten Terjung, Christoph Mahlert, Simone Greven, Anette Sommer, Sandra Berndt
  • Patent number: 11124574
    Abstract: The technology provided herein generally relates to novel specific photoimmuno-theranostics for the use in detection and elimination of skin cancer cells. The technology also relates to novel methods which generate homogeneous and specific photoimmuno-theranostics reagents in a simple, controlled and efficient way. This method combines molecular optical imaging, photodynamic therapy and immunotherapy using SNAP-tag technology.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: September 21, 2021
    Assignee: UNIVERSITY OF CAPE TOWN
    Inventors: Stefan Barth, Ahmad Fawzi Hussain, Rainer Fischer
  • Patent number: 11124571
    Abstract: A method of sensitizing cancer to immunotherapy in a subject in need thereof includes administering to the subject a therapeutically effective amount of a CdK5 inhibitor to suppress immune checkpoint PD-L1.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: September 21, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Alex Yee-Chen Huang, Agne Petrosiute
  • Patent number: 11110179
    Abstract: This invention relates to treatment of cancer using a CD33 antibody drug conjugate in combination with chemotherapeutic agents.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: September 7, 2021
    Assignee: Seagen Inc.
    Inventors: Dana Kennedy, Eric Feldman
  • Patent number: 11103589
    Abstract: The present application provides PEI compounds comprising a linker, PEI-polypeptide conjugates (e.g., PEI-antibody conjugates), and complexes thereof comprising a biologically active molecule. Methods of preparing and using the compounds, conjugates and complexes are further provided. The PEI-polypeptide conjugates and complexes are useful for delivering biologically active molecules to the cytoplasm of cells and promoting release of the biologically active molecules from the endo-lysosomal pathway.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: August 31, 2021
    Assignee: APG Therapeutics, Inc.
    Inventors: Joaquim Trias, Jaume Pons, David Shelton, Antoni Planas
  • Patent number: 11103593
    Abstract: The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: August 31, 2021
    Assignee: SEAGEN INC.
    Inventors: Robert Lyon, Patrick Burke, Joshua Hunter
  • Patent number: 11071788
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: July 27, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Sandra Berndt, Uwe Gritzan, Jenny Fitting, Beatrix Stelte-Ludwig, Patrick Jones, Christoph Mahlert, Christian Votsmeier, Dorian Schönfeld, Mark Trautwein, Ernst Weber, Nikolaus Pawlowski, Simone Greven, Julian Marius Glück, Stefanie Hammer, Lisa Dietz, Stephan Märsch
  • Patent number: 11052085
    Abstract: A method of treating skeletal muscle cachexia and inflammation associated with burn injury in a subject in need thereof is provided, the method including administering to the subject an effective amount of a phosphodiesterase-4B (PED4B)-selective inhibitor.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: July 6, 2021
    Assignees: University of Cincinnati, Shriners Hospital For Children
    Inventors: Ambikaipakan Balasubramaniam, Sulaiman Sheriff
  • Patent number: 11052155
    Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: July 6, 2021
    Assignee: SYNTARGA BV
    Inventors: Patrick Henry Beusker, Rudy Gerardus Elisabeth Coumans, Ronald Christiaan Elgersma, Wiro Michael Petrus Bernardus Menge, Johannes Albertus Frederikus Joosten, Henri Johannes Spijker, Franciscus Marinus Hendrikus De Groot
  • Patent number: 11040084
    Abstract: The present invention provides a conjugate and preparation method thereof, a pharmaceutical composition comprising the conjugate and use of the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: June 22, 2021
    Assignee: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
    Inventors: Gang Qin, Jinduo Yuan, Lu Jiang, Chubing Tan, Lili Shi, Cao Lv, Leilei Chen
  • Patent number: 11027021
    Abstract: This invention relates to treatment of cancer using antibody drug conjugates that comprise PBD molecules in combination with Bcl-2 inhibitors.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: June 8, 2021
    Assignee: Seagen Inc.
    Inventors: William Arthur, Robert Thurman, Travis Biechele, Rory Rohm